Home › Dermatomyositis › Maryland
Dermatomyositis clinical trials in Maryland
9 studies for Dermatomyositis are looking for participants at sites in Maryland.
Cities in Maryland
FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 60 · All sexes · Updated Sep 29, 2026 · NCT07111065Environmental Risk Factors for the Anti-synthetase Syndrome
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 2 to 100 · All sexes · Updated Sep 28, 2026 · NCT01276470Natural History of Inflammatory Muscle Diseases
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 2 to 120 · All sexes · Updated Sep 24, 2026 · NCT05738824A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
- Research Site, Baltimore
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 24, 2026 · NCT06455449Adult and Juvenile Myositis
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 2 to 100 · All sexes · Updated Sep 24, 2026 · NCT00017914Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- National Institutes of Health - Accepting Adult and Juvenile Patients, Bethesda
RecruitingPhase 2/3
Ages 6 to 75 · All sexes · Updated Sep 17, 2026 · NCT06154252A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Johns Hopkins Hospital, Baltimore
RecruitingPhase 1
Ages 18 to 74 · All sexes · Updated Sep 10, 2026 · NCT07085104Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
- Johns Hopkins University, Baltimore
RecruitingPhase 1
Ages 18 to 85 · All sexes · Updated Jul 22, 2026 · NCT06371417From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.